These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 38087370)

  • 1. Targeting the myeloid microenvironment in neuroblastoma.
    Stip MC; Teeuwen L; Dierselhuis MP; Leusen JHW; Krijgsman D
    J Exp Clin Cancer Res; 2023 Dec; 42(1):337. PubMed ID: 38087370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.
    De Sanctis F; Adamo A; Canè S; Ugel S
    Semin Immunopathol; 2023 Mar; 45(2):163-186. PubMed ID: 36161514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.
    Liu KX; Joshi S
    Front Immunol; 2020; 11():1947. PubMed ID: 32983125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate myeloid cells in the tumor microenvironment.
    Duhan V; Smyth MJ
    Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy.
    Zhao J; Dong Y; Zhang Y; Wang J; Wang Z
    Adv Drug Deliv Rev; 2022 Dec; 191():114585. PubMed ID: 36273512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
    Nakamura K; Smyth MJ
    Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
    Zhao Y; Du J; Shen X
    Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
    Tumino N; Weber G; Besi F; Del Bufalo F; Bertaina V; Paci P; Quatrini L; Antonucci L; Sinibaldi M; Quintarelli C; Maggi E; De Angelis B; Locatelli F; Moretta L; Vacca P; Caruana I
    J Hematol Oncol; 2021 Nov; 14(1):191. PubMed ID: 34772439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophils in cancer.
    Treffers LW; Hiemstra IH; Kuijpers TW; van den Berg TK; Matlung HL
    Immunol Rev; 2016 Sep; 273(1):312-28. PubMed ID: 27558343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
    Joshi S; Sharabi A
    Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.
    Wang Y; Johnson KCC; Gatti-Mays ME; Li Z
    J Hematol Oncol; 2022 Aug; 15(1):118. PubMed ID: 36031601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental pathways of myeloid-derived suppressor cells in neoplasia.
    Abrams SI
    Cell Immunol; 2021 Feb; 360():104261. PubMed ID: 33373817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
    Fei L; Ren X; Yu H; Zhan Y
    Front Immunol; 2021; 12():771210. PubMed ID: 34804061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
    Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
    Clin Cancer Res; 2016 Aug; 22(15):3849-59. PubMed ID: 26957560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.